Home › Cancro del polmone non a piccole cellule › Delaware
Studi clinici su Cancro del polmone non a piccole cellule nello stato di Delaware
21 studi su Cancro del polmone non a piccole cellule cercano partecipanti presso sedi nello stato di Delaware.
Città nello stato di Delaware
Testo ufficiale dello studio (inglese)
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
- Beebe South Coastal Health Campus, Millville
- Helen F Graham Cancer Center, Newark
- Medical Oncology Hematology Consultants PA, Newark
- e altri 1
In reclutamentoFase 3
Età 18 e oltre · Tutti i sessi · Aggiornato il 2 ott 2026 · NCT04267848The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
- Medical Oncology Hematology Consultants, Newark
In reclutamentoFase 1/2
Età 12 e oltre · Tutti i sessi · Aggiornato il 2 ott 2026 · NCT04585750Testing the Impact of an Anti-Cancer Drug, Atezolizumab, After Surgery to Prevent Early Stage Non-small Cell Lung Cancer From Returning, AASI-NSCLC Trial
- Beebe South Coastal Health Campus, Millville
- Helen F Graham Cancer Center, Newark
- Medical Oncology Hematology Consultants PA, Newark
- e altri 1
In reclutamentoFase 3
Età 18 e oltre · Tutti i sessi · Aggiornato il 1 ott 2026 · NCT07388524Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial
- Beebe South Coastal Health Campus, Millville
- Helen F Graham Cancer Center, Newark
- Medical Oncology Hematology Consultants PA, Newark
- e altri 1
In reclutamentoFase 3
Età 18 e oltre · Tutti i sessi · Aggiornato il 1 ott 2026 · NCT06498635A Study to Evaluate Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants With Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) (ROSETTA Lung-201)
- Medical Oncology Hematology Consultants, PA, Newark
In reclutamentoFase 3
Età 18 e oltre · Tutti i sessi · Aggiornato il 30 set 2026 · NCT07361497A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)
- Medical Oncology Hematology Consultants, PA, Newark
In reclutamentoFase 3
Età 18 e oltre · Tutti i sessi · Aggiornato il 28 set 2026 · NCT07144280A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)
- Medical Oncology Hematology Consultants Helen F Graham Cancer Center, Newark
In reclutamentoFase 3
Età da 18 a 100 · Tutti i sessi · Aggiornato il 25 set 2026 · NCT05920356A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
- ChristianaCare Helen F Graham Cancer Center and Research Institute, Newark
In reclutamentoFase 2
Età 18 e oltre · Tutti i sessi · Aggiornato il 25 set 2026 · NCT06667076A Study to Investigate Ubamatamab With and Without Marlotamig (REGN7075) in Adult Participants With Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)
- ChristianaCare Health System, Newark
In reclutamentoFase 2
Età 18 e oltre · Tutti i sessi · Aggiornato il 25 set 2026 · NCT07154290A Global Phase III Study of Rilvegostomig or Pembrolizumab Monotherapy for First-Line Treatment of PD-L1-high Metastatic Non-small Cell Lung Cancer
- Research Site, Newark
In reclutamentoFase 3
Età 18 e oltre · Tutti i sessi · Aggiornato il 25 set 2026 · NCT06868277Prospective External Control Cohort In Patients With Newly Diagnosed Advanced or Metastatic EGFR Mutant Non-Small Cell Lung Cancer
- Bayhealth Cancer Center- Kent, Dover
- Bayhealth Cancer Center- Sussex, Milford
In reclutamentoStudio osservazionale
Età 18 e oltre · Tutti i sessi · Aggiornato il 22 set 2026 · NCT07028489An External Control Arm Study in Non-Small Cell Lung Cancer
- Bayhealth Medical Center, Kent Campus, Dover
- Bayhealth Medical Center- Sussex Campus, Milford
In reclutamentoStudio osservazionale
Età 18 e oltre · Tutti i sessi · Aggiornato il 22 set 2026 · NCT07174388A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)
- Medical Oncology Hematology Consultants, PA, Newark
In reclutamentoFase 3
Età 18 e oltre · Tutti i sessi · Aggiornato il 22 set 2026 · NCT06875310A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)
- Research Site, Newark
In reclutamentoFase 3
Età 18 e oltre · Tutti i sessi · Aggiornato il 18 set 2026 · NCT06692738Phase III Study of Datopotamab Deruxtecan Versus Docetaxel in Previously Treated TROP2-positive Advanced or Metastatic Non-squamous NSCLC Without Actionable Genomic Alterations
- Research Site, Newark
In reclutamentoFase 3
Età 18 e oltre · Tutti i sessi · Aggiornato il 4 set 2026 · NCT07291037Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)
- Bayhealth Hospital Kent Campus, Dover
- Bayhealth Hospital Sussex Campus, Milford
In reclutamentoFase 2
Età 18 e oltre · Tutti i sessi · Aggiornato il 3 giu 2026 · NCT05642572Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has Increased Copies of the MET Gene (An Expanded Lung-MAP Treatment Trial)
- Bayhealth Hospital Kent Campus, Dover
- Bayhealth Hospital Sussex Campus, Milford
In reclutamentoFase 2
Età 18 e oltre · Tutti i sessi · Aggiornato il 6 mag 2026 · NCT06116682Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)
- Bayhealth Hospital Kent Campus, Dover
- Bayhealth Hospital Sussex Campus, Milford
In reclutamentoFase 2
18 Minutes · Tutti i sessi · Aggiornato il 5 mag 2026 · NCT06031688Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)
- Beebe South Coastal Health Campus, Millville
- Helen F Graham Cancer Center, Newark
- Medical Oncology Hematology Consultants PA, Newark
- e altri 1
In reclutamentoFase 2/3
Età 18 e oltre · Tutti i sessi · Aggiornato il 5 mag 2026 · NCT06616584Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics
- Beebe South Coastal Health Campus, Millville
- Helen F Graham Cancer Center, Newark
- Medical Oncology Hematology Consultants PA, Newark
- e altri 1
In reclutamentoStudio osservazionale
Età 18 e oltre · Tutti i sessi · Aggiornato il 17 mar 2026 · NCT06418204SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
- Massive Bio SYNERGY-AI site, Newark
In reclutamentoStudio osservazionale
Tutte le età · Tutti i sessi · Aggiornato il 28 ott 2025 · NCT03452774Fonte: ClinicalTrials.gov, dati recuperati il 5 ott 2026. Ogni studio stabilisce i propri criteri di idoneità; è il team di ricerca a decidere chi può partecipare.